Abstracts tagged "myeloperoxidase (MPO) and polymorphism"

Abstract Number: 85 • 2014 ACR/ARHP Annual Meeting
Protective Association of HLA-DRB1*13:02 Against MPO-ANCA Positive ANCA-Associated Vasculitis in a Japanese Population
Naoyuki Tsuchiya¹, Narumi Hasebe¹, Ken-ei Sada², Shigeto Kobayashi³, Hidehiro Yamada⁴, Hiroshi Furukawa⁵, Kunihiro Yamagata⁶, Takayuki Sumida⁷, Nobuyuki Miyasaka⁸, Seiichi Matsuo⁹, Shigeto Tohma⁵, Shoichi Ozaki¹⁰, Hiroshi Hashimoto¹¹, Hirofumi Makino², Masayoshi Harigai¹² and Aya Kawasaki¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁶Department of Internal Medicine (Nephrology), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁸Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁰Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹¹Juntendo University School of Medicine, Tokyo, Japan, ¹²Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose Epidemiology of antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV) is substantially different between European and Asian populations. In the Japanese population, the majority…
Abstract Number: 82 • 2014 ACR/ARHP Annual Meeting
HLA-DPB1^*04:01 Confers Risk for PR3-ANCA Positive ANCA-Associated Vasculitis (AAV), but Protects Against MPO-ANCA Positive AAV, in a Japanese Population
Aya Kawasaki¹, Misaki Hidaka², Narumi Hasebe², Ken-ei Sada³, Shigeto Kobayashi⁴, Hidehiro Yamada⁵, Hiroshi Furukawa⁶, Kunihiro Yamagata⁷, Takayuki Sumida⁸, Nobuyuki Miyasaka⁹, Shigeto Tohma⁶, Shoichi Ozaki¹⁰, Seiichi Matsuo¹¹, Hiroshi Hashimoto¹², Hirofumi Makino³, Masayoshi Harigai¹³ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ³Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁵Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁷Department of Internal Medicine (Nephrology), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁸Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁹Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁰Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹¹Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹²Juntendo University School of Medicine, Tokyo, Japan, ¹³Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose Epidemiologic difference between European and Asian populations is observed in antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV). Granulomatosis with polyangiitis (GPA) is prevalent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].